Turn Therapeutics (NASDAQ:TTRX) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Turn Therapeutics (NASDAQ:TTRX) to a hold rating in a report published on Saturday morning.

TTRX has been the topic of a number of other research reports. Weiss Ratings raised Turn Therapeutics from a “sell (e)” rating to a “sell (d-)” rating in a research report on Monday, July 13th. D. Boral Capital reaffirmed a “buy” rating and set a $8.00 price target on shares of Turn Therapeutics in a research report on Tuesday, March 24th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Turn Therapeutics currently has a consensus rating of “Hold” and an average price target of $8.00.

Turn Therapeutics Trading Up 1.0%

Shares of NASDAQ:TTRX opened at $9.12 on Friday. The firm has a market cap of $271.68 million and a price-to-earnings ratio of -48.00. Turn Therapeutics has a 12 month low of $2.57 and a 12 month high of $26.50. The company’s fifty day simple moving average is $6.34 and its 200 day simple moving average is $4.67. The company has a quick ratio of 2.23, a current ratio of 2.23 and a debt-to-equity ratio of 0.97.

Turn Therapeutics (NASDAQ:TTRX) last announced its earnings results on Monday, May 11th. The company reported ($0.03) earnings per share for the quarter.

Hedge Funds Weigh In On Turn Therapeutics

Hedge funds have recently modified their holdings of the stock. DDFG Inc grew its stake in Turn Therapeutics by 34.9% in the first quarter. DDFG Inc now owns 70,534 shares of the company’s stock valued at $226,000 after purchasing an additional 18,246 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Turn Therapeutics during the 4th quarter worth approximately $99,000. Millennium Management LLC bought a new stake in shares of Turn Therapeutics during the 4th quarter worth approximately $377,000. Tamar Securities LLC acquired a new stake in shares of Turn Therapeutics in the 4th quarter valued at approximately $59,000. Finally, Jane Street Group LLC acquired a new stake in shares of Turn Therapeutics in the 4th quarter valued at approximately $68,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.